Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore

Singapore Medical Journal

Volumn 48, Issue 6, 2007, Pages 504-508

  Winslow, M ^a   Subramaniam, Mythily ^a   Ng, W L ^a   Lee, A ^a   Song, G ^a   Chan, Y H ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug abuse; Hepatitis c virus; Intravenous buprenorphine users; Intravenous drug use; Needle sharing

Indexed keywords

BUPRENORPHINE; HEPATITIS C ANTIBODY; OPIATE; NARCOTIC AGENT;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PREVALENCE; QUESTIONNAIRE; RACE DIFFERENCE; RISK FACTOR; SEROPREVALENCE; SINGAPORE; URINALYSIS; BLOOD; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE TREATMENT; EPIDEMIOLOGY; HEPATITIS C VIRUS; IMMUNOLOGY; MIDDLE AGED; SUBSTANCE ABUSE; VIROLOGY;

ADULT; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NARCOTICS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SINGAPORE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34250866895     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 suppl):S6-9.
2. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-9.
3. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26:521-6.
4. Comment in: Hepatology 1999; 29:299-300.
5. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107:2S-9S.
6. Songsivilai S, Jinathongthai S, Wongsena W, Tiangpitayakorn C, Dharakul T. High prevalence of hepatitis C infection among blood donors in northeastern Thailand. Am J Trop Med Hyg 1997; 57:66-9.
7. Li L, He J, Zhao L. [Epidemiologic features of viral hepatitis in Fujian]. Zhonghua Liu Xing Bing Xue Za Zhi 1998; 19:89-92. Chinese.
8. Kuperan P, Choon AT, Ding SH, Lee G. Prevalence of antibodies to hepatitis C virus in relation to surrogate markers in a blood donor population of Singapore. Southeast Asian J Trop Med Public Health 1993; 24 suppl 1:127-9.
9. Heintges T, Mohr L, Niederau C. [Epidemiology and clinical features of chronic viral hepatitis]. Dtsch Med Wochenschr 1994; 119:1365-70. German.
10. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23:437-55.
11. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91:46-7.
12. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
13. Comment in: N Engl J Med 2001; 345:1425-6; author reply 1427-8.
14. Jauncey M, Micallef JM, Gilmour S, Amin J, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004; 190:1270-4.
15. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36:737-42.
16. Miller M, Mella I, Moi H, Eskild A. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. J Acquir Immune Defic Syndr 2003; 33:373-9.
17. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev 1996; 18:137-48.
18. Vidal-Trecan G, Coste J, Varescon-Pousson I, Christoforov B, Boissonnas A. HCV status knowledge and risk behaviours amongst intravenous drug users. Eur J Epidemiol 2000; 16:439-45.
19. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-6.
20. Comment in: JAMA 2000; 284:2592-3.
21. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115:443-9.
22. Comment in: Ann Intern Med 1992; 116:427.
23. Kemp R. Injecting drug users have high rates of hepatitis C, but HIV infection remains uncommon. New Zealand Public Health Report 1999; 6:17-9.
24. Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005; 19 suppl 3:S20-5.
25. Abraham HD, Degli-Esposti S, Marino L. Seroprevalence of hepatitis C in a sample of middle class substance abusers. J Addict Dis 1999; 18:77-87.
26. Yoong KY, Cheong I. A study of Malaysian drug addicts with human immunodeficiency virus infection. Int J STD AIDS 1997; 8:118-23.
27. Sinniah M, Ooi BG. Hepatitis C - the Malaysian story. Singapore Med J 1993; 34:132-4.
28. Teo SH, Chee KT, Tan CT, Ng BC. Heroin abuse in Singapore - a profile and characteristics study. Singapore Med J 1978; 19:65-70.
29. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34:180-7.
30. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000; 182:1588-94.
31. Hagan H, Thiede H, Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-6.
32. Judd A, Hutchinson S, Wadd S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 2005; 12:655-62.
33. Taylor A, Fleming A, Rutherford J, Goldberg D. Examining the injecting practices of injecting drug users in Scotland. Edinburg: Effective Interventions Unit, 2004.
34. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction 2004; 99:621-33.
35. Centres for Disease Control and Prevention. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta, GA: Centres for Disease Control and Prevention, 1997.